Aegerion Pharmaceuticals (AEGR) : Traders are bullish on Aegerion Pharmaceuticals (AEGR) as it has outperformed the S&P 500 by a wide margin of 86.63% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.82%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8% in the last 1 week, and is up 85.63% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 44.14% and the 50-Day Moving Average is 69.44%.The 200 Day SMA reached 20.91%
Aegerion Pharmaceuticals (NASDAQ:AEGR): The stock opened in the green at $3.03 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $3.1 and a low of $2.69 for the day. The stock did not find buyers even at the lows and closed at $2.97 recording a loss of -2.94%. 994,318 shares exchanged hands during the trading day. The stock had closed at $2.97 in the previous days trading.
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Companys products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein, which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA), as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.